These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 29275847)

  • 1. Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses.
    Vogel AB; Lambert L; Kinnear E; Busse D; Erbar S; Reuter KC; Wicke L; Perkovic M; Beissert T; Haas H; Reece ST; Sahin U; Tregoning JS
    Mol Ther; 2018 Feb; 26(2):446-455. PubMed ID: 29275847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with a low dose of hemagglutinin-encoding plasmid protects against 2009 H1N1 pandemic influenza virus in mice.
    Fang J; Chen Z; Liu X; Li H; Wang J; Shen X; Chen W; Liu Y; Wang Y; Zhao P; Qi Z
    J Virol Methods; 2011 May; 173(2):314-9. PubMed ID: 21392537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses and protective efficacy of a recombinant swinepox virus expressing HA1 against swine H1N1 influenza virus in mice and pigs.
    Xu J; Huang D; Liu S; Lin H; Zhu H; Liu B; Lu C
    Vaccine; 2012 Apr; 30(20):3119-25. PubMed ID: 22391400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge.
    Magini D; Giovani C; Mangiavacchi S; Maccari S; Cecchi R; Ulmer JB; De Gregorio E; Geall AJ; Brazzoli M; Bertholet S
    PLoS One; 2016; 11(8):e0161193. PubMed ID: 27525409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice.
    Wu Y; Yang D; Xu B; Liang W; Sui J; Chen Y; Yang H; Chen H; Wei P; Qiao C
    Antiviral Res; 2017 Nov; 147():29-36. PubMed ID: 28941982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-protection of Lactococcus lactis-displayed HA2 subunit against homologous and heterologous influenza A viruses in mice.
    Lei H; Peng X; Zhao D; Jiao H; Ouyang J
    Arch Virol; 2015 Dec; 160(12):3011-9. PubMed ID: 26358264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity.
    Beissert T; Perkovic M; Vogel A; Erbar S; Walzer KC; Hempel T; Brill S; Haefner E; Becker R; Türeci Ö; Sahin U
    Mol Ther; 2020 Jan; 28(1):119-128. PubMed ID: 31624015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
    Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
    Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of pigs against pandemic swine origin H1N1 influenza A virus infection by hemagglutinin- or neuraminidase-expressing attenuated pseudorabies virus recombinants.
    Klingbeil K; Lange E; Blohm U; Teifke JP; Mettenleiter TC; Fuchs W
    Virus Res; 2015 Mar; 199():20-30. PubMed ID: 25599604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge.
    Wang X; Fu W; Yuan S; Yang X; Song Y; Liu L; Chi Y; Cheng T; Xing M; Zhang Y; Zhang C; Yang Y; Zhu C; Zhang X; Xiong S; Xu J; Zhou D
    Sci Rep; 2017 May; 7(1):1854. PubMed ID: 28500340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aerosol Delivery of a Candidate Universal Influenza Vaccine Reduces Viral Load in Pigs Challenged with Pandemic H1N1 Virus.
    Morgan SB; Hemmink JD; Porter E; Harley R; Shelton H; Aramouni M; Everett HE; Brookes SM; Bailey M; Townsend AM; Charleston B; Tchilian E
    J Immunol; 2016 Jun; 196(12):5014-23. PubMed ID: 27183611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HA1-2-fljB Vaccine Induces Immune Responses against Pandemic Swine-Origin H1N1 Influenza Virus in Mice.
    Kang X; Yang Y; Jiao Y; Song H; Song L; Xiong D; Wu L; Pan Z; Jiao X
    J Mol Microbiol Biotechnol; 2016; 26(6):422-432. PubMed ID: 27721310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.
    Wei CJ; Boyington JC; McTamney PM; Kong WP; Pearce MB; Xu L; Andersen H; Rao S; Tumpey TM; Yang ZY; Nabel GJ
    Science; 2010 Aug; 329(5995):1060-4. PubMed ID: 20647428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
    Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.